ORIC Pharmaceuticals, Inc. ORIC
Set alert
At close · Oct 30
After hours · Oct 30, 4:48 PM ET
- YTD
- +12.96%
- 1 year
- -30.73%
- Open
- 8.87
- Prev close
- 8.99
- Mkt cap
- 957.75M
- Vol
- 2.44M
- Avg vol
- 1.57M
- EPS
- -1.32
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 8.28
- High
- 9.80
- Forward P/E
- -7.87
- Beta
- 0.98
- Short ratio
- 11.16
- Inst. own
- 123.41%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 12, 2026
- 50-d avg
- 12.96
- 200-d avg
- 11.13
- 1y target
- 21.64
News
-
4 days ago benzinga.com
BTIG Reiterates Buy on ORIC Pharmaceuticals, Maintains $26 Price Target
BTIG analyst Jeet Mukherjee reiterates ORIC Pharmaceuticals (NASDAQ:ORIC) with a Buy and maintains $26 price target.
-
5 days ago benzinga.com
Wedbush Maintains Outperform on ORIC Pharmaceuticals, Lowers Price Target to $14
Wedbush analyst David Nierengarten maintains ORIC Pharmaceuticals (NASDAQ:ORIC) with a Outperform and lowers the price target from $17 to $14.
5 days ago defenseworld.net
Oric Pharmaceuticals (NASDAQ:ORIC) Stock Crosses Below 200-Day Moving Average – Should You Sell?
Oric Pharmaceuticals, Inc. (NASDAQ: ORIC - Get Free Report)'s stock price crossed below its 200-day moving average during trading on Monday. The stock has a 200-day moving average of $11.14 and…
6 days ago benzinga.com
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers Surgery Partners (NASDAQ:SGRY) shares moved upwards by 46.9% to $23.14 during Monday's regular session. The market value of their outstanding shares is at $2.0 billion. SciSparc (NASDAQ:SPRC)…
-
6 days ago benzinga.com
Stifel Maintains Buy on ORIC Pharmaceuticals, Raises Price Target to $18
Stifel analyst Laura Prendergast maintains ORIC Pharmaceuticals (NASDAQ:ORIC) with a Buy and raises the price target from $14 to $18.
1 week ago seekingalpha.com
ORIC Pharmaceuticals, Inc. (ORIC) Discusses Enozertinib Phase Ib Data and Commercial Opportunity in EGFR Atypical Non-Small Cell Lung Cancer Transcript
ORIC Pharmaceuticals, Inc. (ORIC) Discusses Enozertinib Phase Ib Data and Commercial Opportunity in EGFR Atypical Non-Small Cell Lung Cancer Transcript
1 week ago marketbeat.com
Oric Pharmaceuticals' Enozertinib Shows 88% Response Rate in EGFR Lung Cancer Study
Oric Pharmaceuticals NASDAQ: ORIC reported updated Phase 1b data for enozertinib in previously untreated patients with advanced non-small cell lung cancer (NSCLC) carrying atypical EGFR mutations,…
-
1 week ago benzinga.com
ORIC Plans Global Phase 3 Redwood-1 Trial Of Enozertinib In 1L EGFR Atypical NSCLC In 1H 2027 After Phase 1b Showing 84% Confirmed Systemic ORR, 70% Confirmed Intracranial ORR
In a 1L EGFR atypical population with more than double the rate of baseline CNS metastases as competitor datasets, enozertinib demonstrates a potential best-in-class 84% confirmed systemic ORR and…
1 week ago globenewswire.com
ORIC® Pharmaceuticals Presents Potential Best-in-Class Data for Enozertinib in 1L NSCLC Patients with EGFR Atypical Mutations at ESMO Congress 2026 and Plans to Advance Enozertinib into a Global Phase 3 Trial
In a 1L EGFR atypical population with more than double the rate of baseline CNS metastases as competitor datasets, enozertinib demonstrates a potential best-in-class 84% confirmed systemic ORR and…
1 week ago globenewswire.com
ORIC® Pharmaceuticals Presents Preclinical and Translational Data to Support the Potential of Rinzimetostat to Enhance Sensitivity to Androgen Receptor Inhibition in Prostate Cancer at ESMO Congress 2026
Preclinical data highlight potential advantages of targeting PRC2 via EED over EZH2, including the emergence of resistance mutations to EZH2 inhibitors like mevrometostat and against which the EED…
1 week ago globenewswire.com
ORIC® Pharmaceuticals to Host Conference Call & Webcast to Review Enozertinib Data Being Presented at ESMO Congress 2026
Conference call and webcast to take place on Friday, October 23, 2026, at 8:00 a.m. ET Event to feature Dr. Joshua Sabari to discuss enozertinib clinical data and the potential of enozertinib to…
2 weeks ago benzinga.com
Meta To Rally More Than 11%? Here Are 10 Top Analyst Forecasts For Wednesday
Analysts raised targets for ACI, ORIC, JPM, SHOP, META and U; KTB upgraded to Buy. Domino’s target was cut.
-
2 weeks ago benzinga.com
JP Morgan Maintains Overweight on ORIC Pharmaceuticals, Raises Price Target to $26
JP Morgan analyst Anupam Rama maintains ORIC Pharmaceuticals (NASDAQ:ORIC) with a Overweight and raises the price target from $23 to $26.
-
3 weeks ago benzinga.com
ORIC Pharmaceuticals Announces Agreement With Cancer Research UK To Advance Potential CIP2A-Targeted Therapy Into Clinical Development
ORIC-259 is a potential first-in-class small molecule mRNA degrader targeting CIP2A, a previously undruggable targetCancer Research UK to fully fund, sponsor, design, and execute CTA-enabling studies…
3 weeks ago globenewswire.com
ORIC® Pharmaceuticals Announces Agreement with Cancer Research UK to Advance a Potential First-in-Class CIP2A-Targeted Therapy Into Clinical Development
ORIC-259 is a potential first-in-class small molecule mRNA degrader targeting CIP2A, a previously undruggable target Cancer Research UK to fully fund, sponsor, design, and execute CTA-enabling…
-
3 weeks ago benzinga.com
Leerink Partners Initiates Coverage On ORIC Pharmaceuticals with Outperform Rating, Announces Price Target of $26
Leerink Partners analyst Asthika Goonewardene initiates coverage on ORIC Pharmaceuticals (NASDAQ:ORIC) with a Outperform rating and announces Price Target of $26.
4 weeks ago globenewswire.com
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Oct. 02, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address…
-
1 month ago benzinga.com
BTIG Initiates Coverage On ORIC Pharmaceuticals with Buy Rating, Announces Price Target of $26
BTIG analyst Jeet Mukherjee initiates coverage on ORIC Pharmaceuticals (NASDAQ:ORIC) with a Buy rating and announces Price Target of $26.
1 month ago seekingalpha.com
ORIC Pharmaceuticals, Inc. (ORIC) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
ORIC Pharmaceuticals, Inc. (ORIC) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
1 month ago globenewswire.com
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Sept.
1 month ago globenewswire.com
ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Sept. 02, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing and commercializing…
-
2 months ago benzinga.com
HC Wainwright & Co. Maintains Buy on ORIC Pharmaceuticals, Raises Price Target to $27
HC Wainwright & Co. analyst Robert Burns maintains ORIC Pharmaceuticals (NASDAQ:ORIC) with a Buy and raises the price target from $25 to $27.
2 months ago defenseworld.net
Dimensional Fund Advisors LP Boosts Holdings in Oric Pharmaceuticals, Inc. $ORIC
Dimensional Fund Advisors LP increased its holdings in shares of Oric Pharmaceuticals, Inc. (NASDAQ: ORIC) by 19.9% during the first quarter, according to its most recent disclosure with the…
2 months ago globenewswire.com
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Aug. 07, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address…
-
2 months ago benzinga.com
ORIC Pharmaceuticals Q2 EPS $(0.38) Misses $(0.36) Estimate
ORIC Pharmaceuticals (NASDAQ:ORIC) reported quarterly losses of $(0.38) per share which missed the analyst consensus estimate of $(0.36) by 5.56 percent. This is a 19.15 percent increase over losses…
2 months ago globenewswire.com
ORIC® Pharmaceuticals Reports Second Quarter 2026 Financial Results and Operational Updates
Initiated Himalayas-1 global Phase 3 trial in patients with mCRPC previously treated with abiraterone Entered into a clinical trial collaboration and supply agreement with Bayer to provide…
3 months ago benzinga.com
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers Tenet Healthcare (NYSE:THC) stock increased by 17.3% to $233.54 during Friday's regular session. The market value of their outstanding shares is at $17.4 billion. The company's, Q2 earnings…
3 months ago seekingalpha.com
ORIC Pharmaceuticals: Royalty-Free Phase 3 Economics Strengthen The Bull Case
ORIC Pharmaceuticals advances rinzimetostat into the global Phase 3 Himalayas-1 trial for mCRPC, with full global rights and royalty-free economics. ORIC's $419.7M cash position funds operations into…
3 months ago globenewswire.com
ORIC® Pharmaceuticals Announces Three Presentations at the European Society for Medical Oncology (ESMO) Congress 2026
Enozertinib poster presentation to highlight data from an ongoing Phase 1b trial in first-line EGFR atypical NSCLC Rinzimetostat trial-in-progress poster presentation to highlight the ongoing…
-
3 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers Agape ATP (NASDAQ:ATPC) shares rose 17.5% to $2.96 during Wednesday's after-market session. The market value of their outstanding shares is at $2.6 million. China Pharma Holding (AMEX:CPHI)…
-
3 months ago benzinga.com
ORIC®Pharmaceuticals Initiates Himalayas-1 Phase 3 Trial in mCRPC Evaluating Rinzimetostat In Combination With NUBEQA
Initiated Himalayas-1 global Phase 3 trial in patients with mCRPC previously treated with abirateroneEntered into a clinical trial collaboration and supply agreement with Bayer to provide…
3 months ago globenewswire.com
ORIC® Pharmaceuticals Announces Initiation of Himalayas-1 Phase 3 Trial in mCRPC Evaluating Rinzimetostat in Combination with NUBEQA® (Darolutamide), Supported by Clinical Collaboration with Bayer
Initiated Himalayas-1 global Phase 3 trial in patients with mCRPC previously treated with abiraterone Entered into a clinical trial collaboration and supply agreement with Bayer to provide…
4 months ago globenewswire.com
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO and SAN DIEGO, July 02, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address…
4 months ago benzinga.com
Bandwidth, Traws Pharma And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Dow futures up 400 points; Bandwidth Inc (BAND) falls after $275M offering; other stocks declining in pre-market trading.
4 months ago seekingalpha.com
ORIC Pharmaceuticals, Inc. (ORIC) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
ORIC Pharmaceuticals, Inc. (ORIC) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
-
4 months ago benzinga.com
HC Wainwright & Co. Reiterates Buy on ORIC Pharmaceuticals, Maintains $25 Price Target
HC Wainwright & Co. analyst Robert Burns reiterates ORIC Pharmaceuticals (NASDAQ:ORIC) with a Buy and maintains $25 price target.
4 months ago globenewswire.com
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, June 05, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address…
-
6 months ago benzinga.com
Citigroup Maintains Buy on ORIC Pharmaceuticals, Lowers Price Target to $16
Citigroup analyst Yigal Nochomovitz maintains ORIC Pharmaceuticals (NASDAQ:ORIC) with a Buy and lowers the price target from $17 to $16.
7 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Intraday Session
12 Health Care Stocks Moving In Wednesday's Intraday Session
-
7 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
7 months ago benzinga.com
Beyond Meat Posts Downbeat Q4 Results, Joins RH, ORIC Pharmaceuticals And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
US stock futures higher with Dow up 200 pts, Beyond Meat shares drop after downbeat results; ORIC, RH, Aptiv, Sweetgreen, Nike, and others also decline.
7 months ago benzinga.com
Why nCino Shares Are Trading Higher By 18%; Here Are 20 Stocks Moving Premarket
Shares of nCino Inc (NASDAQ: NCNO) jumped 18% in pre-market trading after reporting strong Q4 results and issuing positive guidance for Q1 and FY27.
7 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's After-Market Session
12 Health Care Stocks Moving In Tuesday's After-Market Session
-
7 months ago benzinga.com
12 Health Care Stocks Moving In Monday's Intraday Session
12 Health Care Stocks Moving In Monday's Intraday Session
7 months ago benzinga.com
BETA Technologies, Starfighters Space And Other Big Stocks Moving Lower In Monday's Pre-Market Session
U.S. stock futures lower, with Dow futures down over 1%. BETA Technologies (NYSE: BETA) fell in pre-market trading after reporting fourth-quarter results. Other stocks declining in pre-market trading…
7 months ago benzinga.com
Why Lisata Therapeutics Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarket
Lisata Therapeutics (LSTA) surged 20.3% to $5.03 in pre-market trading after agreeing to be taken private by Kuva Labs for $5.00 per share + $1.00 CVR.
8 months ago benzinga.com
Methanex Posts Downbeat Q4 Results, Joins Gap, Nutex Health, Owlet And Other Big Stocks Moving Lower In Friday's Pre-Market Session
U.S. stock futures lower, Dow down 100 points. Methanex (MEOH) shares fall 8.7% after reporting quarterly losses and missed sales estimates.
11 months ago benzinga.com
Top 3 Health Care Stocks That May Rocket Higher In December
Top 3 Health Care Stocks That May Rocket Higher In December
11 months ago benzinga.com
This Helmerich and Payne Analyst Is No Longer Bearish; Here Are Top 3 Upgrades For Friday
This Helmerich and Payne Analyst Is No Longer Bearish; Here Are Top 3 Upgrades For Friday
11 months ago benzinga.com
This Nasdaq Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday
This Nasdaq Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday